

Claudine Isaacs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7011198/publications.pdf>

Version: 2024-02-01

106
papers

9,201
citations

81900

39
h-index

40979

93
g-index

109
all docs

109
docs citations

109
times ranked

11328
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring Racial Differences in Treatment Decision-making in Chinese Immigrant and White American Breast Cancer Patients: the Role of Patient-Provider Communication. <i>Journal of Cancer Education</i> , 2023, 38, 66-73.	1.3	3
2	BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 345-355.	1.6	23
3	Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics. <i>Cancer Medicine</i> , 2022, 11, 297-307.	2.8	2
4	Psychosocial impact of proactive rapid genetic counseling following breast cancer diagnosis. <i>Psycho-Oncology</i> , 2022, 31, 788-797.	2.3	0
5	Association of markers of tumor aggressivity and cognition in women with breast cancer before adjuvant treatment: The Thinking and Living with Cancer Study. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 413-422.	2.5	4
6	Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. <i>Cancer Cell</i> , 2022, 40, 609-623.e6.	16.8	92
7	Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 510-510.	1.6	0
8	Simulation modeling as a tool to support clinical guidelines and care for breast cancer prevention and early detection in high-risk women.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10525-10525.	1.6	0
9	Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 518-518.	1.6	4
10	Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. <i>Journal of the National Cancer Institute</i> , 2021, 113, 54-63.	6.3	98
11	<i>BRCA1/2</i> mutations and risk of reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study. <i>Journal of Genetic Counseling</i> , 2021, 30, 383-393.	1.6	1
12	The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in <i>BRCA1/2</i> -Positive Families. <i>Journal of Cancer Education</i> , 2021, 36, 72-84.	1.3	13
13	Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of <i>HER2</i> -targeted therapies in patients with breast cancer and compromised heart function. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 863-868.	2.5	18
14	Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence score as an exemplar. <i>Patient Education and Counseling</i> , 2021, 104, 250-256.	2.2	3
15	Analysis of immune checkpoint blockade biomarkers in elderly patients using large-scale cancer genomics data.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2543-2543.	1.6	1
16	A simulation model-based clinical decision tool to guide personalized treatment based on individual characteristics: Does 21-gene recurrence score assay testing change decisions?. <i>Journal of Clinical Oncology</i> , 2021, 39, e12507-e12507.	1.6	0
17	Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. <i>Cancer</i> , 2021, 127, 3622-3630.	4.1	8
18	Durvalumab with olaparib and paclitaxel for high-risk <i>HER2</i> -negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. <i>Cancer Cell</i> , 2021, 39, 989-998.e5.	16.8	131

#	ARTICLE	IF	CITATIONS
19	Applying a Life Course Biological Age Framework to Improving the Care of Individuals With Adult Cancers. <i>JAMA Oncology</i> , 2021, 7, 1692.	7.1	22
20	Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis. <i>Biomedicines</i> , 2021, 9, 1111.	3.2	25
21	Evaluating the impact of age on immune checkpoint therapy biomarkers. <i>Cell Reports</i> , 2021, 36, 109599.	6.4	27
22	Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions. <i>Journal of Clinical Oncology</i> , 2021, 39, 2893-2902.	1.6	7
23	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1654.	7.1	42
24	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 131.	5.2	13
25	Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. <i>Nature</i> , 2021, 599, 673-678.	27.8	139
26	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. <i>Nature Communications</i> , 2021, 12, 6428.	12.8	36
27	Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. <i>Translational Behavioral Medicine</i> , 2020, 10, 337-346.	2.4	9
28	Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores. <i>Journal of the National Cancer Institute</i> , 2020, 112, 574-581.	6.3	14
29	Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study. <i>Cancer</i> , 2020, 126, 1183-1192.	4.1	49
30	Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). <i>Journal of Clinical Oncology</i> , 2020, 38, 804-814.	1.6	142
31	Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer. <i>Breast Journal</i> , 2020, 26, 1520-1527.	1.0	17
32	Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 265-275.	2.5	22
33	Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1475.	2.8	11
34	Predictors of genetic testing uptake in newly diagnosed breast cancer patients. <i>Journal of Surgical Oncology</i> , 2020, 122, 134-143.	1.7	3
35	Trends in the Use of Cardiac Imaging for Women with Newly Diagnosed Breast Cancer. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 478-489.	2.4	7
36	Question Prompt List to Support Patient-Provider Communication in the Use of the 21-Gene Recurrence Test: Feasibility, Acceptability, and Outcomes. <i>JCO Oncology Practice</i> , 2020, 16, e1085-e1097.	2.9	11

#	ARTICLE	IF	CITATIONS
37	Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1410.	7.1	161
38	MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1059-1069.	1.6	69
39	Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 676.	7.1	419
40	Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1016-1016.	1.6	3
41	Neratinib: an option for HER2-positive metastatic breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 15, 1-20.	0.3	0
42	Incorporating neratinib into clinical practice for patients with HER2-positive metastatic breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 15, 12-15.	0.3	0
43	Neratinib: an option for HER2-positive metastatic breast cancer-Q&A. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 15, 15-17.	0.3	0
44	Neratinib in the early-stage/extended adjuvant breast cancer patient. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 12, 1-20.	0.3	0
45	Risk of recurrence in early-stage, HER2-positive breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 12, 3-6.	0.3	0
46	Neratinib in the early-stage/extended adjuvant breast cancer patient: Q&A. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 12, 16-17.	0.3	0
47	Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. <i>Breast Journal</i> , 2019, 25, 575-577.	1.0	3
48	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	5.2	28
49	Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz062.	2.9	2
50	Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3132-3132.	1.6	4
51	Simulation modeling of the effects of adjuvant chemotherapy in early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 526-526.	1.6	0
52	Cost Effectiveness of Gene Expression Profile Testing in Community Practice. <i>Journal of Clinical Oncology</i> , 2018, 36, 554-562.	1.6	35
53	Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3211-3222.	1.6	112
54	Risk and Prevention for Highly Penetrant Genes. <i>Current Breast Cancer Reports</i> , 2018, 10, 209-218.	1.0	0

#	ARTICLE	IF	CITATIONS
55	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.9	54
56	Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives. <i>Journal of Health Communication</i> , 2018, 23, 679-686.	2.4	5
57	PLAC1 as a serum biomarker for breast cancer. <i>PLoS ONE</i> , 2018, 13, e0192106.	2.5	19
58	SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1038-1038.	1.6	7
59	Non-BRCA hereditary gene mutations and breast cancer phenotype: An ISC-RAM Consortia study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1540-1540.	1.6	1
60	Pooled analysis of active cigarette smoking and invasive breast cancer risk in 14 cohort studies. <i>International Journal of Epidemiology</i> , 2017, 46, dyw288.	1.9	56
61	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials. <i>Clinical Cancer Research</i> , 2017, 23, 3628-3637.	7.0	99
62	Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). <i>Breast Cancer Research and Treatment</i> , 2017, 164, 107-117.	2.5	68
63	SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. <i>Oncologist</i> , 2017, 22, 518-525.	3.7	31
64	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
65	Randomized Noninferiority Trial of Telephone vs In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer: A 12-Month Follow-Up. <i>JNCI Cancer Spectrum</i> , 2017, 1, pkx002.	2.9	15
66	Circulating microRNAs in patients with hormone receptor–positive, metastatic breast cancer treated with dovitinib. <i>Clinical and Translational Medicine</i> , 2017, 6, 37.	4.0	19
67	How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e72-e78.	3.8	28
68	How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e72-e78.	3.8	40
69	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations. <i>JAMA Oncology</i> , 2016, 2, 1434.	7.1	189
70	Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 23-34.	27.0	467
71	Adaptive Randomization of Neratinib in Early Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 11-22.	27.0	301
72	Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 549-555.	2.5	8

#	ARTICLE	IF	CITATIONS
73	Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). <i>Cancer</i> , 2016, 122, 3555-3563.	4.1	71
74	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
75	An exercise trial to reduce cancer related fatigue in African American breast cancer patients undergoing radiation therapy: Design, rationale, and methods. <i>Contemporary Clinical Trials</i> , 2016, 47, 153-157.	1.8	9
76	Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety. <i>Cancer Prevention Research</i> , 2016, 9, 225-233.	1.5	8
77	Patient Perceptions of Telephone vs. In-Person BRCA1/BRCA2 Genetic Counseling. <i>Journal of Genetic Counseling</i> , 2016, 25, 472-482.	1.6	46
78	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	5.0	26
79	Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1216-1224.	4.9	17
80	Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years. <i>Cancer</i> , 2015, 121, 4062-4070.	4.1	21
81	Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. <i>Genetics in Medicine</i> , 2015, 17, 467-475.	2.4	86
82	Patterns of 21-Gene Assay Testing and Chemotherapy Use in Black and White Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2015, 15, e83-e92.	2.4	7
83	Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data. <i>Journal of Oncology Practice</i> , 2015, 11, e1-e8.	2.5	12
84	The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2911-2915.	7.0	77
85	Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	7.4	390
86	SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 58-64.	1.6	89
87	Cognitive Impairment in Older Patients With Breast Cancer Before Systemic Therapy: Is There an Interaction Between Cancer and Comorbidity?. <i>Journal of Clinical Oncology</i> , 2014, 32, 1909-1918.	1.6	129
88	Treatment of primary breast tumors in de novo metastatic breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 820-7.	0.3	10
89	Supplement use during an intergroup clinical trial for breast cancer (S0221). <i>Breast Cancer Research and Treatment</i> , 2013, 137, 903-913.	2.5	31
90	Narrowing racial gaps in breast cancer chemotherapy initiation: the role of the patient-provider relationship. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 207-216.	2.5	51

#	ARTICLE	IF	CITATIONS
91	Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS. <i>Journal of Cancer Epidemiology</i> , 2012, 2012, 1-8.	1.1	14
92	Long-term outcomes of <i>BRCA1/BRCA2</i> testing: risk reduction and surveillance. <i>Cancer</i> , 2012, 118, 510-517.	4.1	117
93	<i>BRCA1/2</i> test results impact risk management attitudes, intentions, and uptake. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 755-764.	2.5	25
94	Association of Risk-Reducing Surgery in <i>BRCA1</i> or <i>BRCA2</i> Mutation Carriers With Cancer Risk and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 967.	7.4	1,241
95	Tamoxifen and the risk of ovarian cancer in <i>BRCA1</i> mutation carriers. <i>Gynecologic Oncology</i> , 2009, 115, 135-137.	1.4	13
96	Randomized trial of a decision aid for <i>BRCA1/BRCA2</i> mutation carriers: Impact on measures of decision making and satisfaction.. <i>Health Psychology</i> , 2009, 28, 11-19.	1.6	94
97	Perceived risk of breast cancer among Latinas attending community clinics: risk comprehension and relationship with mammography adherence. <i>Cancer Causes and Control</i> , 2008, 19, 1373-1382.	1.8	40
98	Cancer Yield of Mammography, MR, and US in High-Risk Women: Prospective Multi-Institution Breast Cancer Screening Study. <i>Radiology</i> , 2007, 244, 381-388.	7.3	361
99	¹³⁵ C Modifies Breast Cancer Risk among <i>BRCA2</i> Mutation Carriers: Results from a Combined Analysis of 19 Studies. <i>American Journal of Human Genetics</i> , 2007, 81, 1186-1200.	6.2	217
100	Screening mammography and risk of breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: a case-control study. <i>Lancet Oncology</i> , The, 2006, 7, 402-406.	10.7	104
101	Breast Cancer Risk Following Bilateral Oophorectomy in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: An International Case-Control Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 7491-7496.	1.6	408
102	Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: The PROSE Study Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 1055-1062.	1.6	1,095
103	Impact of <i>BRCA1/BRCA2</i> Counseling and Testing on Newly Diagnosed Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2004, 22, 1823-1829.	1.6	270
104	Impact of educational print materials on knowledge, attitudes, and interest in <i>BRCA1/BRCA2</i> . <i>Cancer</i> , 2001, 92, 932-940.	4.1	88
105	Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2710-2717.	1.6	108
106	Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 478-478.	1.6	243